{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:11:00Z","timestamp":1762506660166,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ando.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T07:08:02Z","timestamp":1445929682000},"page":"679-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Valuable predictive features of relapse of Graves\u2019 disease after antithyroid drug treatment"],"prefix":"10.1016","volume":"76","author":[{"given":"Xingjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2015.08.004_bib0120","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1530\/eje.0.1430639","article-title":"Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Tr\u00f8ndelag (HUNT)","volume":"143","author":"Bjoro","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2015.08.004_bib0125","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves\u2019 disease","volume":"147","author":"Nedrebo","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2015.08.004_bib0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-121-4-199408150-00010","article-title":"Treatment of hyperthyroid disease","volume":"121","author":"Klein","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2015.08.004_bib0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1507\/endocrj.K10E-262","article-title":"Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves\u2019 disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission","volume":"58","author":"Konishi","year":"2011","journal-title":"Endocr J"},{"key":"10.1016\/j.ando.2015.08.004_bib0140","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2009.0126","article-title":"Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves\u2019 disease","volume":"20","author":"Choo","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2015.08.004_bib0145","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(05)65600-0","article-title":"Is there one successful antithyroid regimen for Graves\u2019 disease?","volume":"348","author":"Braverman","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2015.08.004_bib0150","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/jcem-26-8-803","article-title":"Long-term outcome of hyperthyroidism treated with antithyroid drugs","volume":"26","author":"Hershman","year":"1966","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.08.004_bib0155","first-page":"221","article-title":"Early remission in thyrotoxicosis produced by short courses of treatment","volume":"100","author":"Bing","year":"1982","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.ando.2015.08.004_bib0160","first-page":"619","article-title":"Outcome of Graves\u2019 disease after antithyroid drug treatment in Taiwan","volume":"97","author":"Wang","year":"1998","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ando.2015.08.004_bib0165","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bmj.298.6670.359","article-title":"Optimum duration of antithyroid drug treatment determined by assay of thyroid-stimulating antibody in patients with Graves\u2019 disease","volume":"298","author":"Edan","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2015.08.004_bib0170","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1507\/endocrj.K06-069","article-title":"Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves\u2019 disease: a 120 months prospective study","volume":"54","author":"Cappelli","year":"2007","journal-title":"Endocr J"},{"key":"10.1016\/j.ando.2015.08.004_bib0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment","volume":"7","author":"Vitti","year":"1997","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2015.08.004_bib0180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-13-0811","article-title":"Long-term prognosis after medical treatment of Graves\u2019 disease in a northern Swedish population 2000\u20132010","volume":"170","author":"Mohlin","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2015.08.004_bib0185","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","article-title":"Administration of thyroxine in treated Graves\u2019 disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism","volume":"324","author":"Hashizume","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2015.08.004_bib0190","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJM199601253340403","article-title":"Lack of effect of thyroxine in patients with Graves\u2019 hyperthyroidism who are treated with an antithyroid drug","volume":"334","author":"McIver","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2015.08.004_bib0195","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/s-0034-1377045","article-title":"A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves\u2019 disease","volume":"122","author":"Liu","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ando.2015.08.004_bib0200","doi-asserted-by":"crossref","first-page":"510","DOI":"10.7326\/0003-4819-107-4-510","article-title":"Remission rates with antithyroid drug therapy: continuing influence of iodine intake?","volume":"107","author":"Solomon","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2015.08.004_bib0205","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem-61-2-374","article-title":"Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter","volume":"61","author":"Azizi","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.08.004_bib0210","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF03344113","article-title":"Restriction of dietary iodine does not ameliorate the early effect of antithyroid drug therapy for Graves\u2019 disease in an area of excessive iodine intake","volume":"29","author":"Hiraiwa","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2015.08.004_bib0215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000375261","article-title":"Excessive iodine intake does not increase the recurrence rate of Graves\u2019 disease after withdrawal of the antithyroid drug in an iodine-replete area","volume":"4","author":"Park","year":"2015","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2015.08.004_bib0220","first-page":"689","article-title":"Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves\u2019 disease","volume":"120","author":"Schleusener","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.ando.2015.08.004_bib0225","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/thy.2005.15.1047","article-title":"Sensitive thyrotropin and thyrotropin -receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves\u2019 disease","volume":"15","author":"Quadbeck","year":"2005","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2015.08.004_bib0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1507\/endocrj.50.45","article-title":"Practical treatment with minimum maintenance dose of antithyroid drugs for prediction of remission in Graves\u2019 disease","volume":"50","author":"Kashiwai","year":"2003","journal-title":"Endocr J"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426615010835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426615010835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:48:26Z","timestamp":1757717306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426615010835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0003426615010835"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2015.08.004","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valuable predictive features of relapse of Graves\u2019 disease after antithyroid drug treatment","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}